Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Jan 30, 2006

Dynamic growth in 2005 full-year consolidated net sales: up 9.3% on a comparable basis
Jan 18, 2006

FDA grants priority review to PLAVIX® (clopidogrel bisulfate) Supplemental New Drug Application (sNDA) for additional type of heart attack

Filing for STEMI Indication Also Submitted in Europe
Jan 13, 2006

Pfizer to purchase Sanofi-aventis rights to EXUBERA® in application of change of control clauses
Jan 4, 2006

Procter & Gamble Pharmaceuticals and Sanofi-aventis US LLC file lawsuit against Roche Pharmaceuticals and Glaxosmithkline

Lawsuit Alleges Advertising for Once-a-Month Osteoporosis Drug Misleads Physicians and Consumers
Dec 13, 2005

PLAVIX® (clopidogrel bisulfate) recommended as effective cardiovascular risk reduction treatment for patients with established Peripheral Arterial Disease (P.A.D.)
Dec 8, 2005

Interim analysis of phase III study shows TAXOTERE®-based regimens with HERCEPTIN® significantly improved disease free survival in women with early-stage HER2-positive breast cancer
Dec 6, 2005

New analysis ranks America’s worst cities for respiratory infections
Dec 2, 2005

FDA Grants Priority Review to Taxotere® for the Supplemental New Drug Application for Advanced Gastric Cancer
Nov 16, 2005

New England Journal of Medicine publishes the RIO-Lipids study
Nov 15, 2005

Study shows that intra-articular hyaluronate therapy HYALGAN® (sodium hyaluronate) is effective in treating chronic shoulder pain due to osteoarthritis
Nov 15, 2005

Analysis from several clinical studies show dronedarone appears to be consistently safe and effective in maintaining normal sinusal rhythm and ventricular rate control in patients with cardiac arrhythmia
Nov 8, 2005

Third quarter 2005: Adjusted EPS up 27.4%, net sales up 11.0% on a comparable basis - First 9 months of 2005: Adjusted EPS up 26.6%, net sales up 11.0% on a comparable basis
Nov 7, 2005

New data show long-term (52 week) use of ALVESCO® (ciclesonide) had a low incidence of oropharyngeal side effects in patients with mild-to-moderate asthma
Oct 20, 2005

EXUBERA® inhaled insulin improves blood sugar levels in adults with type 2 diabetes better than diabetes pills alone
Oct 7, 2005

AMBIEN CR™ now available in the US
Sep 29, 2005

Hearing date set on motion for preliminary injunction in ALLEGRA® (fexofenadine hcl) patent infringement case
Sep 29, 2005

Sanofi-aventis provides relief to hurricane victims
Sep 20, 2005

FDA accepts filed pre-market approval supplement to expand the indication for HYALGAN® (sodium hyaluronate) to include shoulder pain due to osteoarthritis
Sep 15, 2005

INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE® (docetaxel)- BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® (trastuzumab) SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER
Sep 14, 2005

Study Finds Alvesco® (ciclesonide) Did Not Affect HPA-Axis Function in Patients with Moderate-to-Severe Persistent Asthma
Sep 12, 2005

Sanofi-aventis Group enters agreement with Prasco Laboratories to market generic versions of ALLEGRA® (fexofenadine HCl)
Sep 8, 2005

FDA Advisory Committee recommends Approval of EXUBERA® for use in adults with type 1 and type 2 diabetes
Sep 6, 2005

AMBIEN CR™ (zolpidem tartrate extended-release tablets) CIV receives FDA Approval for the treatment of insomnia
Aug 31, 2005

Strong growth in 2005 first half adjusted EPS : up 26.1% at €2.22. Increase in full year adjusted EPS guidance. Positive phase IIb/III results for 6 products
Aug 18, 2005

Taxotere® Significantly Improves Survival Compared with paclitaxel In Women With Advanced Breast Cancer

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.